文献速递儿科与产科急症重症综合管理与镇静镇痛

镰状细胞病与贫血孕妇的严重孕产妇并发症及其他不良妊娠结局比较

Comparisons of Severe Maternal Morbidity and Other Adverse Pregnancy Outcomes in Pregnant People With Sickle Cell Disease vs Anemia.
PubMed 文献 · JAMA Netw Open · 2023-02-01
一句话结论在黑人产妇中,镰状细胞病(SCD)与产前贫血均与严重孕产妇并发症(SMM)风险升高相关,且两者在许多缺血或胎盘异常相关并发症上的风险相似,提示产前贫血可能是SCD妊娠风险的介导因素。

这项横断面研究利用2012至2018年美国全国住院患者样本中764455例黑人产妇分娩住院数据,比较SCD组(3200例)、贫血组(34808例)和对照组(726447例)的严重孕产妇并发症(SMM)及其他不良妊娠结局。结果显示,SCD组和贫血组的SMM调整比值比(aOR)分别为5.51(95%CI 4.71-6.45)和2.00(95%CI 1.84-2.17),均高于对照组。对于缺血或胎盘异常相关并发症(如子痫),SCD组与贫血组的aOR置信区间重叠,SCD vs 贫血的RR在1.0-2.1之间;而对于血栓或SCD特异性并发症,SCD组的发生率和aOR均高于贫血组,RR在3.70-10.90之间。作者认为,产前贫血可能是SCD患者妊娠风险的介导因素。

要点

  • 在黑人产妇中,SCD组SMM发生率为5.9%(95%CI 5.1%-6.8%),贫血组为2.1%(95%CI 2.0%-2.3%),对照组为1.1%(95%CI 1.0%-1.1%);SCD组和贫血组SMM的aOR分别为5.51(95%CI 4.71-6.45)和2.00(95%CI 1.84-2.17)。
  • SCD组孕产妇死亡率为每10 000次分娩13.0例(95%CI 4.9-35.0),贫血组为0.9例(95%CI 0.3-2.8),对照组为1.2例(95%CI 1.0-1.5)。
  • 对于缺血或胎盘异常相关并发症(如子痫),SCD组与贫血组的aOR置信区间重叠(子痫:aOR 2.74,95%CI 1.51-4.96 vs aOR 1.40,95%CI 1.08-1.81),SCD vs 贫血的RR在1.0-2.1之间(子痫RR 1.76,95%CI 0.93-3.32)。
  • 对于血栓或SCD特异性并发症,SCD组的发生率和aOR均高于贫血组,RR在3.70-10.90之间;例如急性呼吸窘迫综合征(包括急性胸部综合征)发生率SCD组为56/3144(1.8%),贫血组为122/34686(0.4%),RR 4.99(95%CI 3.65-6.84)。
  • 作者认为,产前贫血可能是SCD患者妊娠风险的介导因素,因为SCD与贫血在许多不良妊娠结局上的风险相似。

适用人群与场景

  • 美国全国住院患者样本中2012至2018年所有年龄11至55岁、编码为分娩且仅纳入黑人种族的住院患者。
  • 分娩住院患者按编码分为三组: maternal SCD组(3200例)、 maternal anemia组(34808例)和对照组(726447例)。

诊断标准与关键阈值

  • 严重孕产妇并发症(SMM)按美国疾病控制与预防中心(CDC)SMM指数进行统计。
  • 其他不良妊娠结局(APOs)包括子痫、急性呼吸窘迫综合征(包括急性胸部综合征)等。

研究设计与关键结果

  • 研究类型:横断面研究,使用美国全国住院患者样本(NIS)2012至2018年数据,共纳入764455例黑人产妇分娩住院,其中SCD组3200例、贫血组34808例、对照组726447例;平均(SD)分娩年龄27.00(6.08)岁;多数患者为公共保险(499060例,65.4%)。
  • 主要终点:SMM发生率SCD组5.9%(95%CI 5.1%-6.8%),贫血组2.1%(95%CI 2.0%-2.3%),对照组1.1%(95%CI 1.0%-1.1%);与对照组相比,SCD组aOR 5.51(95%CI 4.71-6.45),贫血组aOR 2.00(95%CI 1.84-2.17)。
  • 孕产妇死亡率(每10 000次分娩):SCD组13.0例(95%CI 4.9-35.0),贫血组0.9例(95%CI 0.3-2.8),对照组1.2例(95%CI 1.0-1.5)。
  • 缺血或胎盘异常相关并发症:SCD组与贫血组的aOR置信区间重叠,例如子痫aOR 2.74(95%CI 1.51-4.96) vs aOR 1.40(95%CI 1.08-1.81);SCD vs 贫血的RR在1.0-2.1之间,例如子痫RR 1.76(95%CI 0.93-3.32)。
  • 血栓或SCD特异性并发症:SCD组的发生率和aOR均高于贫血组,RR在3.70-10.90之间;例如急性呼吸窘迫综合征(包括急性胸部综合征)发生率SCD组56/3144(1.8%) vs 贫血组122/34686(0.4%),RR 4.99(95%CI 3.65-6.84)。

证据类型、等级与局限

  • 证据类型:横断面研究,使用全国住院患者样本数据库。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,产前贫血可能是SCD患者妊娠风险的介导因素,因为SCD与贫血在许多不良妊娠结局上的风险相似。

指南或共识出处

  • 美国疾病控制与预防中心(CDC)严重孕产妇并发症(SMM)指数。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Pregnancy in sickle cell disease (SCD) is high risk, but whether prenatal anemia, which is treatable with red blood cell transfusions, is a mediator associated with adverse pregnancy outcomes (APOs) is not known.

OBJECTIVE: To compare rates and odds of severe maternal morbidity (SMM) and other APOs in pregnancies among individuals with SCD vs those without SCD but with prenatal anemia.

DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study was conducted using data from 2012 to 2018 from the National Inpatient Sample, a nationally representative sample of 20% of acute hospital admissions in the United States. All admissions with codes for delivery of a pregnancy among people aged 11 to 55 years were included. Only admissions coded with Black race were included. Data were analyzed from September 2021 through August 2022.

EXPOSURES: Prenatal anemia and SCD.

MAIN OUTCOMES AND MEASURES: SMM was tabulated per the Center for Disease Control and Prevention SMM Index alongside other APOs. Multiple logistic regression was used to compare the odds for APOs and risk ratios (RRs) to compare rates of APOs.

RESULTS: Among 764 455 total delivery admissions among patients identified as Black (mean [SD] age at delivery, 27.00 [6.08] years), 3200 deliveries were coded with maternal SCD, 34 808 deliveries were coded with maternal anemia, and 726 447 deliveries were control. Most patients were publicly insured (499 060 [65.4%]). For most outcomes, including SMM and mortality per 10 000 deliveries, the SCD group had higher rates (SMM: 5.9%; 95% CI, 5.1%-6.8%; maternal mortality: 13.0 deaths; 95% CI, 4.9 to 35.0 deaths) than anemia (SMM: 2.1%; 95% CI, 2.0%-2.3%; maternal mortality: 0.9 deaths; 95% CI, 0.3 to 2.8 deaths) or control groups (SMM: 1.1%; 95% CI, 1.0%-1.1%; maternal mortality: 1.2 deaths; 95% CI, 1.0 to 1.5 deaths). SCD (adjusted odds ratio [aOR], 5.51; 95% CI, 4.71-6.45) and anemia groups (aOR, 2.00; 95% CI, 1.84-2.17) had higher adjusted odds of SMM compared with the control group. However, for many complications associated with ischemia or abnormal placentation, CIs of aORs for SCD and anemia groups overlapped (eg, eclampsia: aOR, 2.74; 95% CI, 1.51-4.96 vs aOR, 1.40; 95% CI, 1.08-1.81). For these complications, RRs for SCD vs anemia were between 1.0 and 2.1 (eg, eclampsia: 1.76; 95% CI, 0.93-3.32). For complications associated with thrombosis or SCD-specific pathologies, rates and aORs were greater for the SCD vs anemia group. For these complications, RRs were between 3.70 and 10.90. For example, rates of acute respiratory distress syndrome, including acute chest syndrome, were 56 of 3144 deliveries (1.8%) vs 122 of 34 686 deliveries (0.4%), and the RR was 4.99 (95% CI, 3.65-6.84).

CONCLUSIONS AND RELEVANCE: This study found that risks associated with prenatal anemia and SCD were similar for many APOs, especially those associated with ischemia and abnormal placentation, suggesting that prenatal anemia may be a mediator associated with pregnancy risk in individuals with SCD.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Early ML, Eke AC, Gemmill A, et al. Comparisons of Severe Maternal Morbidity and Other Adverse Pregnancy Outcomes in Pregnant People With Sickle Cell Disease vs Anemia. JAMA Netw Open. 2023. PMID: 36729453. doi:10.1001/jamanetworkopen.2022.54545

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。